PRME (Prime Medicine) Total Equity: $76.70 Mil (As of Mar. 2026)


PRME Prime Medicine Inc PRME
25 GF Score
Price $3.18
! 4 Warning Signs
View Full Analysis

What is Prime Medicine Total Equity?

Prime Medicine PRME +2.09% 25 Total Equity is $76.70 Mil as of Mar. 2026. GuruFocus rates PRME with a GF Score™ of 25/100. The stock has 4 warning signs investors should review.

Prime Medicine's total equity for the quarter that ended in Mar. 2026 was $76.70 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Prime Medicine Total Equity Historical Data

* Premium members only.

The historical data trend for Prime Medicine's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prime Medicine Total Equity Chart

Prime Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 239.56 316.27 133.07 153.15 120.87

Prime Medicine Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 106.92 60.86 161.82 120.87 76.70
PRME
25GF Score
Prime Medicine Inc PRME
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prime Medicine Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Prime Medicine's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=342.733-221.865
=120.87

Prime Medicine's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=294.73-218.03
=76.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $76.70 Mil mean?
Prime Medicine (PRME) has a Total Equity of $76.70 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Prime Medicine and its competitors.
Is Prime Medicine's Total Equity too high?
Prime Medicine's current Total Equity is $76.70 Mil. Overall, Prime Medicine has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's Total Equity compare to IMMX and SGP?
Prime Medicine's Total Equity of $76.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Prime Medicine and its competitors. Prime Medicine's current Total Equity is $76.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current Total Equity of $76.70 Mil. The current Total Equity is $76.70 Mil. Prime Medicine's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Prime Medicine (PRME), the current Total Equity is $76.70 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prime Medicine Business Description

Address 60 First Street, Cambridge, MA, USA, 02141
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
25GF Score

Get the complete analysis for PRME

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.18
Price